{"id":666,"date":"2006-07-01T12:01:00","date_gmt":"2006-07-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/eine-zweite-chance-fuer-natalizumab"},"modified":"2006-07-01T12:01:00","modified_gmt":"2006-07-01T10:01:00","slug":"eine-zweite-chance-fuer-natalizumab","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/eine-zweite-chance-fuer-natalizumab","title":{"rendered":"Eine zweite Chance f\u00fcr Natalizumab"},"content":{"rendered":"<p>Im M\u00e4rz 2006 wurden im N. Engl. J. M. zwei Studien zur Therapie der Multiplen Sklerose (MS) mit Natalizumab (Tysabri\u00ae) publiziert, einmal in Form einer Monotherapie (1), einmal in Kombination mit Interferon beta-1a (2). Beide Studien ergaben einen deutlich besseren Effekt, als die derzeit zugelassenen Standardtherapien, gemessen an Schubrate, Zahl der MRT-L\u00e4sionen und der \u00c4nderung [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im M\u00e4rz 2006 wurden im N. Engl. J. M. zwei Studien zur Therapie der Multiplen Sklerose (MS) mit Natalizumab (Tysabri\u00ae) publiziert, einmal in Form einer Monotherapie (1), einmal in Kombination mit Interferon beta-1a (2). Beide Studien ergaben einen deutlich besseren Effekt, als die derzeit zugelassenen Standardtherapien, gemessen an Schubrate, Zahl der MRT-L\u00e4sionen und der \u00c4nderung [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1648,352,989,992,991,990,1647],"class_list":["post-666","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-affirm-studie","tag-multiple-sklerose","tag-natalizumab","tag-pml","tag-polyomaviren","tag-progressive-multifokale-leukoenzephalopathie","tag-sentinel-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=666"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/666\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}